Home/Pipeline/APG-1387

APG-1387

Chronic Hepatitis B

Phase 2Active

Key Facts

Indication
Chronic Hepatitis B
Phase
Phase 2
Status
Active
Company

About Ascentage Pharma Group

Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.

View full company profile

About Ascentage Pharma Group

Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.

View full company profile

Therapeutic Areas

Other Chronic Hepatitis B Drugs